ARPE-19 as a platform cell line for encapsulated cell-based delivery
AssigneeNeurotech S.A.
InventorsWeng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B. I. Goddard
Life of this patent
Estimating the term…
Abstract
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
Claims3
A method of delivering a growth factor to a recipient host having a retinal degenerative disorder, comprising the steps of:
- (a) encapsulating an ARPE-19 cell within a semipermeable membrane . . . wherein the target region is in the eye, and wherein the ARPE-19 cell is genetically engineered to secrete CNTF.
A method for inhibiting chronic tissue degradation in the eye of a host having a retinal degenerative disorder, comprising implanting into the corresponding tissue of a recipient host an implantable cell culture device, the device comprising:
- (a) a semipermeable membrane permitting the diffusion of a therapeutic protein therethrough, wherein the therapeutic protein is ciliary neurotrophic factor (CNTF);
- and
- (b) at least one ARPE-19 cell disposed within the semipermeable membrane, wherein the ARPE-19 cell is genetically engineered to secrete the therapeutic protein;
- wherein the device secretes a therapeutically effective amount of protein into the targeted tissue of the host recipient.
Dependencies are inferred from the claim text.